Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other financing activities: 2020-2023

Historic Other financing activities for 4D Molecular Therapeutics (FDMT) over the last 2 years, with Jun 2023 value amounting to $260,000.

  • 4D Molecular Therapeutics' Other financing activities rose 128.07% to $260,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $437,000, marking a year-over-year increase of 21.39%. This contributed to the annual value of $468,000 for FY2022, which is N/A change from last year.
  • As of Q2 2023, 4D Molecular Therapeutics' Other financing activities stood at $260,000, which was up 276.81% from $69,000 recorded in Q1 2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Other financing activities peaked at $946,000 during Q1 2021, and registered a low of -$946,000 during Q4 2021.
  • Moreover, its 3-year median value for Other financing activities was $180,000 (2022), whereas its average is $99,625.
  • Data for 4D Molecular Therapeutics' Other financing activities shows a peak YoY increase of 149.47% (in 2022) and a maximum YoY decrease of 74.00% (in 2022) over the last 5 years.
  • 4D Molecular Therapeutics' Other financing activities (Quarterly) stood at -$348,000 in 2020, then skyrocketed by 140.10% to -$946,000 in 2021, then surged by 149.47% to $468,000 in 2022, then spiked by 128.07% to $260,000 in 2023.
  • Its Other financing activities was $260,000 in Q2 2023, compared to $69,000 in Q1 2023 and $468,000 in Q4 2022.